BBQ und Craftbeer @WarPigs_Brewpub 🥰🍻 #mbcc25 #craftbeer #copenhagen #jockwasherpodcast #thegermanatmizzou

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer ALISCA-Breast1 is investigating alisertib plus endocrine therapy in HR-positive, HER2-negative recurrent or metastatic breast cancer.

Alisertib Plus Endocrine Therapy Is Under Evaluation in HR+/HER2-Negative Metastatic Breast Cancer #gotoPER #MBCC25 #bcsm www.onclive.com/view/alisert...

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups Neratinib-containing combinations are consistently effective across CNS end points in patients with HER2-positive breast cancer brain metastases.

Neratinib Generates CNS Responses Across HER2+ Breast Cancer Brain Metastases Subgroups #gotoPER #MBCC25 #bcsm www.onclive.com/view/neratin...

Superb research that’ll save lives.

👏🏽👏🏽👏🏽👏🏽👏🏽

Thanks for highlighting @onclive.bsky.social

#MBCC25 #bcsm #CancerX

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer Promising new agents are in development to address the unmet need resulting from resistance to endocrine therapy plus CDK4/6 inhibition in breast cancer.

SERDs, PROTAC, and CERANs Offer Hope Following ET/CDK4/6 Inhibitor Resistance in Breast Cancer @hoperugo.bsky.social @ucsfcancer.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/serds-p...

Puppy 🐶 parks are the best new trends in medical conferences. Love em!

#MBCC25

Definitely hit the paws 🐾 button if you’re at #MBCC25.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer Preliminary data showed atirmociclib plus letrozole yielded antitumor activity in HR-positive/HER2-negative metastatic breast cancer.

Atirmociclib Plus Letrozole Demonstrates Preliminary Efficacy and Safety in HR+/HER2-Negative Metastatic Breast Cancer @danafarber.bsky.social #gotoPER #MBCC25 #bcsm www.onclive.com/view/atirmoc...

I found the puppies at Miami Breast and they made me soooo happy #MBCC25

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases Sara A. Hurvitz, MD, FACP, discusses the growing role of systemic therapy in HER2-positive breast cancer brain metastases.

Systemic Therapies Are Now Preferred in Some Patients With HER2+ Breast Cancer Brain Metastases @fredhutch.bsky.social #gotoPER #MBCC25 #bcsm #oncology www.onclive.com/view/systemi...

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions Patients with high-risk, early breast cancer receiving adjuvant abemaciclib maintained benefit with the agent regardless of dose modification.

Abemaciclib Delivers Consistent Benefit in High-Risk, Early Breast Cancer Regardless of Dose Reductions @bswhealth.bsky.social @texasoncology.bsky.social #MBCC25 #gotoPER #bcsm #oncology
www.onclive.com/view/abemaci...

Definite bonus of Miami Breast #MBCC25

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups Benefits were seen with abemaciclib/fulvestrant regardless of metastatic site in HER2-negative advanced breast cancer following prior CDK4/6 inhibition.

Abemaciclib/Fulvestrant Improves PFS Across HR+/HER2– Advanced Breast Cancer Subgroups #MBCC25 #bcsm #oncology www.onclive.com/view/abemaci...

HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options Sara A. Hurvitz, MD, FACP, offers insight on the use of (neo)adjuvant therapies in HER2-positive early breast cancer, and how to best optimize treatment.

HER2+ Early Breast Cancer: Tailoring Therapy in the Era of Expanding Options @fredhutch.bsky.social #MBCC25 #bcsm #oncology www.onclive.com/view/her2-ea...

PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer PF-07248144 plus fulvestrant was safe and generated responses in pretreated estrogen receptor–positive, HER2-negative metastatic breast cancer.

PF-07248144 Plus Fulvestrant Is Safe, Active in Pretreated ER+/HER2– Metastatic Breast Cancer #MBCC25 #bcsm #oncology www.onclive.com/view/pf-0724...

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer Imlunestrant generated PFS benefit with or without abemaciclib for select patients with ER-positive, HER2-negative advanced breast cancer.

Imulnestrant Plus Abemaciclib Extends PFS Over SOC in ER+/HER2– Advanced Breast Cancer #BCSM #oncology #MBCC25
www.onclive.com/view/imulnes...

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population Treatment with sacituzumab govitecan was effective and tolerable in real-world patients with mTNBC who received the agent in later-line settings.

Sacituzumab Govitecan Upholds Efficacy and Safety in Real-World mTNBC Population
#BCSM #oncology #MBCC25 @upmchillmancc.bsky.social
www.onclive.com/view/sacituz...

Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2– mBC The real-world use of ribociclib plus ET is in line with recommended dosing and the regimen’s use has been increasing in mBC, according to EHR and KRD data.

Real-World Findings Support the Safety of Frontline Ribociclib Plus ET for HR+/HER2– mBC #BCSM #oncology #MBCC25
www.onclive.com/view/real-wo...

Ribociclib Efficacy Is Maintained With Dose Reductions in Hormone Receptor+/HER2-Negative Early Breast Cancer A post hoc analysis of the NATALEE trial suggests that ribociclib dose reduction preserves iDFS in hormone receptor+/HER2-negative early breast cancer.

Ribociclib Efficacy Is Maintained With Dose Reductions in Hormone Receptor+/HER2-Negative Early Breast Cancer #MBCC25

www.onclive.com/view/ribocic...

Meet Scout! Our AI-trained search tool is designed to help answer your clinical questions. There is a display located near the registration desk at #MBCC25 - give it a try and let us know what you think! #gotoPER #bcsm

We're jumping into day 2 of #MBCC25 with some incredible discussions, including a CE-Certified Satellite Symposium Coffee Talk™ on HER2, HER3, and TROP2 in breast cancer care, facilitated by Hope Rugo, MD, and colleagues. Stay tuned for more live updates! #gotoPER #bcsm

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC Sacituzumab govitecan was active with low rates of neutropenia—especially in patients receiving G-CSF—in real-world metastatic TNBC.

Sacituzumab Govitecan Produces Comparable Real-World OS Results, Low Rates of Neutropenia in Metastatic TNBC #gotoPER #MBCC25 #bcsm #oncology www.onclive.com/view/sacituz...

Just landed and looking forward to the sessions tomorrow! Hope to connect with some of you! #MBCC25

That's a wrap on Day 1 of the 42nd Annual Miami Breast Cancer Conference! Check back on our site over the next few days as the research coverage and KOL insights from this meeting take the stage #MBCC25 #gotoPER #bcsm
www.onclive.com/conference/m...

42nd Annual Miami Breast Cancer Conference: The Show and After Show Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the many advantages to attending the 42nd Annual Miami Breast Cancer Conference, with some additional tidbits to round out the main event.

OncLive is gearing up for the 42nd Annual Miami Breast Cancer Conference! Co-hosts Kristie L. Kahl and Andrew Svonavec highlight the advantages of attending the meeting in the video below!

Click the link to watch!🔗 www.onclive.com/view/42nd-an...

#bcsm #MBCC25 #MedTwitter